Table 2.
TE and major bleeding events according to the antithrombotic treatment, gender and CHADS2 score
|
Total (%) |
Antithrombotic treatment at the time of event occurrence |
|||
|---|---|---|---|---|
| Warfarin* | Antiplatelet | Untreated | ||
|
Thromboembolic events |
12 (0.97) |
5 |
6 |
1 |
| Stroke |
4 |
2 |
2 |
0 |
| TIA |
4 |
1 |
2 |
1 |
| Systemic embolism |
4 |
2 |
2 |
0 |
| Female |
9 |
4 |
5 |
0 |
| Male |
3 |
1 |
1 |
1 |
| CHADS2 score |
|
|
|
|
| 0 |
1 |
1 |
0 |
0 |
| 1 |
4 |
2 |
1 |
1 |
| ≥ 2 |
7 |
2 |
5 |
0 |
|
Major bleeding events |
10 (0.81) |
5 |
5 |
0 |
| Intracranial bleeding |
5 |
3 |
2 |
0 |
| Systemic bleeding |
5 |
2 |
3 |
0 |
| Female |
7 |
5 |
2 |
0 |
| Male |
3 |
0 |
3 |
0 |
| CHADS2 score |
|
|
|
|
| 0 |
1 |
1 |
0 |
0 |
| 1 |
4 |
1 |
3 |
0 |
| ≥ 2 | 5 | 3 | 2 | 0 |
*Includes patients taking both warfarin and antiplatelet treatment.